Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma

HIGHLIGHTS

• What: The aim of this mixed Chimeric antigen receptor (CAR) T-cell therapy (CAR T therapy) has transformed treatment paradigms for patients with B-cell malignancies, including leukemia, lymphoma, and multiple myeloma . This study provides additional evidence of general acceptance and agreement among clinical CAR T experts with outpatient experience that cilta-cel can be administered safely in an outpatient setting, as supported by 4 recent studies demonstrating the safety and feasibility of cilta-cel administration in the outpatient setting . This mixed methods qualitative study combining a targeted literature review with expert interviews and panels evaluated the . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.